Lyra Therapeutics, Inc.
5.50%
98,301
1327273
55234L204
Nov 13, 2025
Nov 18, 2025, 04:14 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Perceptive Advisors LLC | Investment Adviser | 5.50% | 98,301 | 0 | 98,301 |
| Joseph Edelman | Individual | 5.50% | 98,301 | 0 | 98,301 |
| Perceptive Life Sciences Master Fund, Ltd. | CO | 5.00% | 88,374 | 0 | 88,374 |
| Perceptive LS (A), LLC | CO | 0.60% | 9,927 | 0 | 9,927 |
Disclosure Items (2)
Common Stock, $0.001 par value
Lyra Therapeutics, Inc.
480 Arsenal Way, Watertown, MA, 02472
Items 5(a)-(c) of the Schedule 13D are amended and supplemented as follows: The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 1,774,882 outstanding shares of Common Stock as of November 7, 2025 as reported by the Issuer in its Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2025.
The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.
Except as set forth on Schedule A, no Reporting Person has effected any transaction in shares of Common Stock since the filing of Amendment No. 8 to the Schedule 13D, filed with the Securities and Exchange Commission on November 13, 2025.